1
|
Andrade RB, Cohen-Paes ADN, Leal DFDVB, Pantoja KBCC, Gellen LPA, de Carvalho DC, Piedade de Souza T, Fernandes MR, de Assumpcão PP, Burbano RMR, dos Santos SEB, dos Santos NPC. Impact of pri-let-7a-1 rs10739971 for Gastric Cancer Predisposition in an Amazon Region. Genes (Basel) 2023; 14:453. [PMID: 36833380 PMCID: PMC9956087 DOI: 10.3390/genes14020453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 12/31/2022] [Accepted: 01/04/2023] [Indexed: 02/12/2023] Open
Abstract
Gastric cancer (GC) is the fifth most common type of cancer and the fourth leading cause of cancer death. In Brazil, GC has a high incidence and mortality rates, and it is highly variable by region. The Amazon region has significant rising rates among all Brazil regions. Only very few studies have evaluated the association between genetic variants and the risk of gastric cancer in the Brazilian Amazon population. Therefore, this study aimed to investigate associations between single nucleotide polymorphisms of miRNA processing genes and the risk for GC in this population. Potentially functional single nucleotide polymorphisms from miRNA processing genes were genotyped in 159 cases and 193 healthy controls by QuantStudio Real Time PCR. According to our findings, the genotype GG of the variant rs10739971 presents a lower risk to the development of GC in comparison to the remaining genotypes (p = 0.000016; OR = 0.055; 95% CI = 0.015-0.206). This is the first study to report the association of pri-let-7a-1 rs10739971 with GC in the Brazilian Amazon population, which is a highly mixed population with a unique genetic constitution that is different from other populations that are studied in the vast majority of scientific research.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Rommel Mario Rodríguez Burbano
- Oncology Research Center, Federal University of Pará, Belém 66073-000, Pará, Brazil
- Ophir Loyola Hospital, Molecular Biology Laboratory, Belém 66063-240, Pará, Brazil
| | | | | |
Collapse
|
2
|
Vaziri MRR, Ranjbar S, Beigzadeh AM, Sharif S. Experimental investigation and simultaneous modeling of the effect of methylene blue addition to cancer tumors in photodynamic therapy by digital holography. Photodiagnosis Photodyn Ther 2022; 40:103153. [PMID: 36228979 DOI: 10.1016/j.pdpdt.2022.103153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 09/20/2022] [Accepted: 10/07/2022] [Indexed: 11/05/2022]
Abstract
BACKGROUND Although many types of cancers can be treated with surgery, alternatives such as photodynamic therapy with simultaneous use of photosensitive materials and illumination can also be used. Knowing the dose of absorbed energy from the light beam in the photo-sensitized tumors and tissues has an important role in designing the optimal irradiation method with the aim of investigating the amount of received damage to the healthy and tumor tissues. METHODS In this study, the effect of the presence of methylene blue sensitizer on the amount of dose received in tissue-equivalent material has been investigated experimentally by Mach-Zehnder interferometry and digital holography. The Monte Carlo method and the ValoMC code have been used to confirm the results obtained in the experimental phase. RESULTS The results indicate the positive role of methylene blue in increasing the absorbed dose of tumor-equivalent material. The amount of light dose increase and the two-dimensional profile of the dose absorbed in tissue and tumor equivalent materials have been measured by digital holography. CONCLUSIONS The method presented in this work can be used in treatment design and real time measuring of the spatially resolved distribution of the absorbed dose in the tissues containing tumors.
Collapse
Affiliation(s)
| | - Sepideh Ranjbar
- Applied Physics Group, Faculty of Physics and Energy Engineering, Amirkabir University of Technology, Tehran, Iran
| | - Amir Mohammad Beigzadeh
- Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
| | - Samaneh Sharif
- Medical Genetics Research Center, Mashhad University of Medical Sciences, Azadi square, Mashhad, Iran.
| |
Collapse
|
3
|
Oryani MA, Tavasoli A, Ghalavand MA, Ashtiani RZ, Rezaee A, Mahmoudi R, Golvari H, Owrangi S, Soleymani-Goloujeh M. Epigenetics and its therapeutic potential in colorectal cancer. Epigenomics 2022; 14:683-697. [PMID: 35473313 DOI: 10.2217/epi-2022-0067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
It is estimated that colorectal cancer (CRC) is the leading cause of cancer-related death around the globe. 'Epigenetics' refers to changes in the chromosome rather than the DNA sequence, which may be transmitted down to daughter cells. Epigenetics is an essential part of controlling the development and variation of a single cell. ncRNAs have a role in epigenetic regulation in CRC, which will be discussed in this review in the context of DNA methylation and histone modifications. A greater survival rate for CRC patients might be achieved by addressing epigenetic mediators, as the authors show. In this review, they aim to thoroughly examine the role of epigenetics in the prognosis, diagnosis and treatment of CRC.
Collapse
Affiliation(s)
- Mahsa Akbari Oryani
- Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Afsaneh Tavasoli
- Department of Biotechnology, Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran
| | - Mohammad Amin Ghalavand
- Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
| | | | - Alisam Rezaee
- Faculty of Medical Sciences & Technologies, Science & Research Branch, Islamic Azad University, Tehran, Iran
| | | | - Hossein Golvari
- School of Nursing & Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran
| | - Soroor Owrangi
- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
| | - Mehdi Soleymani-Goloujeh
- Department of Stem Cells & Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology & Technology, ACECR, Tehran, Iran
| |
Collapse
|
4
|
Mousazadeh L, Mousazadeh B, Motaei J, Abbasi F, Esfehani RJ. Preclinical and clinical aspects of using Tazemetostate in human cancers. Curr Pharm Des 2022; 28:1329-1333. [DOI: 10.2174/1381612828666220408121514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Accepted: 02/02/2022] [Indexed: 11/22/2022]
Abstract
Abstract:
Epigenetic drugs are novel drug categories with promising effects in different cancers. Tazemetostate is among the drugs that were recently used in clinical settings, especially in the treatment of specific tumors and lymphomas. There are a growing number of ongoing clinical trials evaluating the safety and efficacy of tazemetostate in different cancers. The present review addressed the available preclinical studies evaluating the combination of tazemetostate and other chemotherapy agents in treating different cancers and summarized the limited clinical evidence available regarding the efficacy of this novel Enhancer of Zeste Homolog 2 (EZH2) inhibitor in cancer. Based on the available clinical studies, tazemetostate could be considered a safe epigenetic agent with limited adverse events for treating specific types of lymphomas and solid tumors. However, the superiority of using tazemetostate over other chemotherapy agents in patients with cancer as well as using the drug for other clinical conditions including non-alcoholic steatohepatitis needs further investigation. Moreover, the effect of tazemetostate on human germline cells is clearly evaluated as some animal studies demonstrated that the drug can affect germline epigenome suggesting further studies on this issue.
Collapse
Affiliation(s)
- Leila Mousazadeh
- Department of Nursing, Kurdistan Technical Institute, Sulaymaniyah, Iraq
| | - Behzad Mousazadeh
- Department of Medical laboratory science, Kurdistan Technical Institute, Sulaymaniyah, Iraq
| | - Jamshid Motaei
- Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Faezeh Abbasi
- Department of Internal Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Reza Jafarzadeh Esfehani
- Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR)- Khorasan Razavi, Mashhad, Iran
- Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|